CP
PHAT icon

Catalys Pacific’s Phathom Pharmaceuticals PHAT Stock Holding History

Catalys Pacific’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.2M Hold
1,493,854
– – 7.06% 2
2026
Q1 		$16.6M Buy
1,493,854
+64,840
+5% +$819K 7.19% 2
2025
Q4 		$23.7M Buy
1,429,014
+261,900
+22% +$3.74M 7.63% 2
2025
Q3 		$13.7M Hold
1,167,114
– – 3.91% 2
2025
Q2 		$11.2M Hold
1,167,114
– – 8.5% 2
2025
Q1 		$7.32M Hold
1,167,114
– – 4.92% 2
2024
Q4 		$9.48M Buy
1,167,114
+44,542
+4% +$552K 8.18% 2
2024
Q3 		$20.3M Buy
1,122,572
+400,610
+55% +$5.6M 16.19% 2
2024
Q2 		$7.44M Hold
721,962
– – 5.61% 3
2024
Q1 		$7.67M Hold
721,962
– – 5.18% 3
2023
Q4 		$6.59M Buy
+721,962
New +$6.22M 6.18% 3

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GKIM
GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Catalys Pacific's PHAT Position: Q2 2026 in Review

Catalys Pacific held its Phathom Pharmaceuticals (PHAT) position steady in Q2 2026 at 1,493,854 shares worth $16.2M. The position accounts for 7.06% of the portfolio, ranked #2.

Catalys Pacific first reported a position in PHAT in Q4 2023 and has held it in 11 quarters since. The position peaked at $23.7M in Q4 2025. 162 funds tracked by Wall St. Rank hold PHAT as of Q2 2026.

  • Catalys Pacific held 1,493,854 shares of Phathom Pharmaceuticals worth $16.2M as of Q2 2026.
  • Catalys Pacific left its Phathom Pharmaceuticals share count unchanged in Q2 2026.
  • Phathom Pharmaceuticals made up 7.06% of Catalys Pacific's portfolio in Q2 2026, its #2 holding.
  • Catalys Pacific first reported a position in Phathom Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
  • Catalys Pacific's Phathom Pharmaceuticals position peaked at $23.7M in Q4 2025.
  • 162 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2026.

Based on Catalys Pacific's 13F filing for Q2 2026, filed 5 Aug 2026.